Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Sees Significant Growth in Short Interest

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 13,527 shares, a growth of 55.1% from the January 15th total of 8,723 shares. Based on an average daily trading volume, of 20,855 shares, the short-interest ratio is presently 0.6 days. Currently, 1.5% of the company’s stock are sold short. Currently, 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 20,855 shares, the short-interest ratio is presently 0.6 days.

Virtus LifeSci Biotech Clinical Trials ETF Price Performance

BBC traded down $0.43 during trading on Friday, hitting $39.87. The stock had a trading volume of 13,941 shares, compared to its average volume of 26,768. The stock has a 50 day simple moving average of $40.17 and a two-hundred day simple moving average of $32.12. Virtus LifeSci Biotech Clinical Trials ETF has a twelve month low of $13.42 and a twelve month high of $44.10.

Virtus LifeSci Biotech Clinical Trials ETF Company Profile

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.